Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • asthma (5)
  • eosinophil (4)
  • eosinophil count (1)
  • eosinophilia (1)
  • ex smokers (3)
  • female (2)
  • function (3)
  • humans (1)
  • ics (3)
  • lung (1)
  • neutrophil (3)
  • patients (5)
  • smoking (2)
  • sputum (7)
  • sputum eosinophilia (3)
  • steroid (3)
  • Sizes of these terms reflect their relevance to your search.

    This study aims to investigate the relationship between induced sputum eosinophilia and pulmonary functions in ex-smoker asthma patients controlled with an ICS/LABA therapy. Asthma patients who are known to use ICS/LABA regularly for at least three months, without an attack in the last month, quit smoking (5-20 pack-years) and have asthma under control (ACT> 20), and concurrent with induced sputum cytology who had spirometry and lung volume measurements were included in the study. Cytology results, induced sputum eosinophil and neutrophil counts, FEV1 (L), FEV1 (%), FVC (L), FVC (%), RV (L), RV (%) and RV/TLC (%) values of all patients were recorded. The relationship between sputum neutrophil and eosinophil count and pulmonary function test parameters was evaluated. Seventeen (68%) of the patients were female, eight (32%) were male, and the mean age was 49.7 ± 13.6 years. The mean sputum eosinophil percentage was 9.4 ± 16.7, and the neutrophil percentage was 71.4 ± 20.5. A positive correlation was found between induced sputum eosinophil percentage values and FEV1 (L) (r= +0.472; p= 0.01) and FVC (L) (r= +0.502; p= 0.01). No correlation was found between the FEV1/FVC%, FEV1%, FVC%, RV (L), RV%, and RV/TLC% values and the percentage of induced sputum eosinophils (p> 0.05). It was observed that controlled asthmatic patients with induced sputum eosinophilia treated with ICS/LABA and who quit smoking had high FVC (L) and FEV1 (L) levels.


    Buket Çalışkaner Öztürk, Şermin Börekçi, Nail Yılmaz, Bilun Gemicioğlu. Induced sputum eosinophilia and pulmonary function tests in ex-smokers with asthma controlled with an inhaled steroid and long-acting beta-agonist therapy. Tuberkuloz ve toraks. 2022 Dec;70(4):334-340

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36537090

    View Full Text